NCT05235269View on ClinicalTrials.gov

A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

February 24, 2023

Conditions
Amyloidosis
Interventions
DRUG

124I-AT-01

All participants received 1 mCi 124I-AT-01 on Day 1 and at Week 6 via IV infusion over 2-5 minutes or slow IV bolus at 1 mL/5 seconds.

Trial Locations (3)

94705

PET/CT Imaging of Berkeley, Berkeley

95128

PET/CT Imaging of San Jose, San Jose

95816

Northern California PET Imaging Center, Sacramento

Sponsors

Lead Sponsor

Attralus, Inc.
All Listed Sponsors
lead

Attralus, Inc.

INDUSTRY

NCT05235269 - A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis | Biotech Hunter | Biotech Hunter